![](https://premierconsulting.com/wp-content/uploads/2022/03/Data-Floating_Orange_Blog-Featured-Image-740x400.png)
Maximizing FDA PIND Feedback With an Optimized Nonclinical Strategy: 4 Tips to Streamlining Your Path to Clinic
By William Salminen, Madelyn Huang, & Andrew Emanuel Without concrete guidelines, it can be confusing when determining what nonclinical studies are needed for a Pre-Investigational New Drug application (PIND) meeting. However, in our experience, the answer is this: it is critical that the nonclinical program